内皮素(endothelin,ET)和一氧化氮(nitric oxide,NO)作为一对最为重要的内皮依赖性舒血管因子和缩血管因子,它们的平衡在血管损伤性疾病中的地位越来越引起人们的关注.目前,一氧化氮信号通路和内皮素轴为靶点的药物如硝酸酯类和波生坦(Bosentan)已在临床心血管系统疾病中广泛使用,在恶性肿瘤侵袭转移进程中的良好治疗作用成为新的领域值得期待,对于两者的平衡及其交互通路的研究已成为当前热点.该文着重论述最近有关ET和NO平衡及其药物的研究进展,希望能为研究工作者提供参考.%Endothelin-l( ET-1 ) and nitric oxide ( NO ) have long been valued as two dominant indicators for evaluating endothelial injury. Accumulating evidence indicates their crucial roles in pathogenesis of various vascular diseases. Currently, drugs targeting NO signaling and ET-1 axis such as nitrate and bosentan have been widely used in the clinic for treating cardiovascular diseases. Moreover, these drugs are expected to be useful in malignant tumor therapy. Studies on the equilibrium and the crosstalk between ET and NO have become a hot topic. This review focuses on the recent progress on the molecular mechanisms underlying the role of NO and endothelin-1 implicated in diseases as well as the targeting drug discovery and development. These novel insights will provide guidelines for future investigations in this field.
展开▼
